The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

AZURE (BIG01/04) Investigators; R E Coleman; M C Winter; D Cameron; R Bell; D Dodwell; M M Keane; M Gil; D Ritchie; J L Passos-Coelho; D Wheatley; R Burkinshaw; S J Marshall; H Thorpe

doi:10.1038/sj.bjc.6605604

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

AZURE (BIG01/04) Investigators, R E Coleman, M C Winter, D Cameron, R Bell, D Dodwell, M M Keane, M Gil, D Ritchie, J L Passos-Coelho, D Wheatley, R Burkinshaw, S J Marshall, H Thorpe

Research output: Contribution to journal › Article › peer-review

Abstract

Pre-clinical studies have demonstrated synergistic anti-tumour effects of chemotherapy (CT) and zoledronic acid (ZOL). Within the AZURE trial, designed to determine whether the addition of ZOL to neoadjuvant therapy improves disease outcomes, a subgroup received neoadjuvant CT. We report a retrospective evaluation comparing pathological response in the primary tumour between treatment groups.

Original language	English
Pages (from-to)	1099-105
Number of pages	7
Journal	British Journal of Cancer
Volume	102
Issue number	7
DOIs	https://doi.org/10.1038/sj.bjc.6605604
Publication status	Published - 2010

Access to Document

10.1038/sj.bjc.6605604

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response exploratory evidence for direct anti-tumour activity in breast cancer
Available under Open Access
Final published version, 333 KB

http://www.nature.com/bjc/journal/v102/n7/full/6605604a.html

Cite this

AZURE (BIG01/04) Investigators, Coleman, R. E., Winter, M. C., Cameron, D., Bell, R., Dodwell, D., Keane, M. M., Gil, M., Ritchie, D., Passos-Coelho, J. L., Wheatley, D., Burkinshaw, R., Marshall, S. J., & Thorpe, H. (2010). The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. British Journal of Cancer, 102(7), 1099-105. https://doi.org/10.1038/sj.bjc.6605604

@article{32fc78925d274eb6b514d58821a49ab0,

title = "The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer",

abstract = "Pre-clinical studies have demonstrated synergistic anti-tumour effects of chemotherapy (CT) and zoledronic acid (ZOL). Within the AZURE trial, designed to determine whether the addition of ZOL to neoadjuvant therapy improves disease outcomes, a subgroup received neoadjuvant CT. We report a retrospective evaluation comparing pathological response in the primary tumour between treatment groups.",

author = "{AZURE (BIG01/04) Investigators} and Coleman, {R E} and Winter, {M C} and D Cameron and R Bell and D Dodwell and Keane, {M M} and M Gil and D Ritchie and Passos-Coelho, {J L} and D Wheatley and R Burkinshaw and Marshall, {S J} and H Thorpe",

year = "2010",

doi = "10.1038/sj.bjc.6605604",

language = "English",

volume = "102",

pages = "1099--105",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "7",

}

AZURE (BIG01/04) Investigators, Coleman, RE, Winter, MC, Cameron, D, Bell, R, Dodwell, D, Keane, MM, Gil, M, Ritchie, D, Passos-Coelho, JL, Wheatley, D, Burkinshaw, R, Marshall, SJ & Thorpe, H 2010, 'The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer', British Journal of Cancer, vol. 102, no. 7, pp. 1099-105. https://doi.org/10.1038/sj.bjc.6605604

TY - JOUR

T1 - The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response

T2 - exploratory evidence for direct anti-tumour activity in breast cancer

AU - AZURE (BIG01/04) Investigators

AU - Coleman, R E

AU - Winter, M C

AU - Cameron, D

AU - Bell, R

AU - Dodwell, D

AU - Keane, M M

AU - Gil, M

AU - Ritchie, D

AU - Passos-Coelho, J L

AU - Wheatley, D

AU - Burkinshaw, R

AU - Marshall, S J

AU - Thorpe, H

PY - 2010

Y1 - 2010

N2 - Pre-clinical studies have demonstrated synergistic anti-tumour effects of chemotherapy (CT) and zoledronic acid (ZOL). Within the AZURE trial, designed to determine whether the addition of ZOL to neoadjuvant therapy improves disease outcomes, a subgroup received neoadjuvant CT. We report a retrospective evaluation comparing pathological response in the primary tumour between treatment groups.

AB - Pre-clinical studies have demonstrated synergistic anti-tumour effects of chemotherapy (CT) and zoledronic acid (ZOL). Within the AZURE trial, designed to determine whether the addition of ZOL to neoadjuvant therapy improves disease outcomes, a subgroup received neoadjuvant CT. We report a retrospective evaluation comparing pathological response in the primary tumour between treatment groups.

U2 - 10.1038/sj.bjc.6605604

DO - 10.1038/sj.bjc.6605604

M3 - Article

C2 - 20234364

VL - 102

SP - 1099

EP - 1105

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 7

ER -

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

Abstract

Access to Document

Fingerprint

Cite this